- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | BIO-WORKS TECHNOLOGIES AB: Today is the first day of the eighth exercise period for Bio-Works Technologies AB's warrants of series TO 2 | 1 | Cision News | ||
| BIO-WORKS TECHNOLOGIES Aktie jetzt für 0€ handeln | |||||
| Do | BIO-WORKS TECHNOLOGIES AB: Bio-Works Technologies AB - Business Update third quarter 2026 | 1 | Cision News | ||
| 27.08. | BIO-WORKS TECHNOLOGIES AB: Bio-Works brings forward the publication of its interim report for the third quarter of 2026 | 1 | Cision News | ||
| 25.08. | BIO-WORKS TECHNOLOGIES AB: Bio-Works Secures New US Customer in the Development of Next-Generation Medicine | 2 | Cision News | ||
| 21.08. | BIO-WORKS TECHNOLOGIES AB: Bio-Works reports second quarter 2026 | 1 | Cision News | ||
| 18.08. | BIO-WORKS TECHNOLOGIES AB: Bio-Works Technologies AB appoints Eva Lindskog as new CEO | 1 | Cision News | ||
| 17.07. | BIO-WORKS TECHNOLOGIES AB: Bio-Works Receives Order for 22,6 MSEK from Returning Customer | 2 | Cision News | ||
| 15.07. | BIO-WORKS TECHNOLOGIES AB: Bio-Works Technologies AB announces outcome from exercise of warrants of series TO 2. Exercise period 7 of 11 | 1 | Cision News | ||
| 06.07. | BIO-WORKS TECHNOLOGIES AB: Bio-Works Receives Order for 8,9 MSEK from Returning Customer | 1 | Cision News | ||
| 01.07. | BIO-WORKS TECHNOLOGIES AB: Today is the first day of the seventh exercise period for Bio-Works Technologies AB's warrants of series TO 2 | 1 | Cision News | ||
| 01.07. | BIO-WORKS TECHNOLOGIES AB: Bio-Works Technologies AB - Business Update second quarter 2026 | 1 | Cision News | ||
| 04.06. | BIO-WORKS TECHNOLOGIES AB: Resolutions passed at Bio-Works Technologies' annual general meeting 2026 | 1 | Cision News | ||
| 13.05. | BIO-WORKS TECHNOLOGIES AB: Bio-Works reports first quarter 2026 | 2 | Cision News | ||
| 29.04. | BIO-WORKS TECHNOLOGIES AB: Bio-Works receives order for WorkBeads 40S from contract manufacturer in Europe | 1 | Cision News | ||
| 17.04. | BIO-WORKS TECHNOLOGIES AB: Bio-Works Technologies AB announces outcome from exercise of warrants of series TO 2. Exercise period 6 of 11 | 8 | Cision News | ||
| 10.04. | BIO-WORKS TECHNOLOGIES AB: Proposed New Board Members in Bio-Works | 1 | Cision News |
16 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| HELIX BIOPHARMA | 0,474 | +0,85 % | Helix BioPharma Corp (2): Helix BioPharma appoints Loeffler as CMO | ||
| DAMORA THERAPEUTICS | 20,690 | +0,19 % | Damora Therapeutics, Inc.: Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| QIAGEN | 40,405 | +5,80 % | Microsoft, Newron, Pyrum, Qiagen, Börse München - das 4investors.de-Weekend | Was hat Anleger am Wochenende bewegt? Hier sind die 4investors.de-Berichte vom Wochenende mit spannenden Aktien-Stories zu Microsoft, Newron, Pyrum, Qiagen sowie der Börsenpresseschau der Börse München.... ► Artikel lesen | |
| CG ONCOLOGY | 67,38 | 0,00 % | CG Oncology Inc.: CG Oncology Reports Second Quarter 2026 Financial Results and Provides Business Updates | PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy as an adjuvant therapy in intermediate-risk NMIBC anticipated in the near-termBLA completion for HR BCG-unresponsive NMIBC expected... ► Artikel lesen | |
| HARMONY BIOSCIENCES | 39,640 | 0,00 % | Harmony Biosciences Announces Poster Presentation at the 17th European Narcolepsy Days | ||
| TARSUS PHARMACEUTICALS | 73,00 | 0,00 % | Tarsus Pharmaceuticals, Inc: Tarsus Plans to Present 11 Abstracts Highlighting New Insights in Demodex Blepharitis, Ocular Rosacea and the Real-World Impact of XDEMVY at the American Academy of Optometry 2026 Annual Meeting | ||
| PRAXIS PRECISION MEDICINES | 295,78 | +0,09 % | Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| VERA THERAPEUTICS | 30,420 | 0,00 % | Vera Therapeutics Announces ORIGIN 3 Final Efficacy Analysis of TRUTAKNA (atacicept-vymj) in IgA Nephropathy Will be A Featured Late-breaking Oral Presentation at the Opening Plenary Session of ASN Kidney Week 2026 | BRISBANE, Calif., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a commercial-stage biotechnology company, today announced that there will be multiple presentations at the... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 16,755 | 0,00 % | Astrazeneca investiert 2 Mrd USD in Summit Therapeutics - Kooperation vertieft | DJ Astrazeneca investiert 2 Mrd USD in Summit Therapeutics - Kooperation vertieft
Von Elias Schisgall
DOW JONES--Astrazeneca investiert im Rahmen einer erweiterten Partnerschaft 2 Milliarden... ► Artikel lesen | |
| TANGO THERAPEUTICS | 23,225 | -0,06 % | Tango Therapeutics, Inc.: Tango Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights | Company continues to prepare for late-stage clinical advancement of vopimetostat in combination with daraxonrasib for pancreatic cancer following positive Phase 1/2 data Phase 1/2 data from combination... ► Artikel lesen | |
| MONTE ROSA THERAPEUTICS | 10,500 | 0,00 % | Monte Rosa Therapeutics, Inc.: Monte Rosa Therapeutics Announces Positive Results for MRT-8102 in GFORCE-1 Phase 1 Study Showing Normalization of Key Pathogenic Drivers of ASCVD in Subjects with Elevated CVD Risk | In obese subjects at elevated cardiovascular disease (CVD) risk, MRT-8102, a NEK7-directed molecular glue degrader in development for the treatment of NLRP3/IL-1-driven inflammatory diseases, normalized... ► Artikel lesen | |
| MBX BIOSCIENCES | 58,51 | 0,00 % | Guggenheim raises MBX Biosciences price target to $150 on obesity drug potential | ||
| EDGEWISE THERAPEUTICS | 41,400 | 0,00 % | Edgewise Therapeutics Reports Second Quarter 2026 Financial Results | - Announced positive top-line data from 12-week Phase 2 CIRRUS-HCM trial with EDG-7500 in obstructive and nonobstructive hypertrophic cardiomyopathy (HCM) -
- ... ► Artikel lesen | |
| AMYLYX PHARMACEUTICALS | 27,790 | 0,00 % | Stifel reiterates Amylyx stock rating on avexitide confidence | ||
| KYMERA THERAPEUTICS | 107,37 | -0,02 % | B.Riley reiterates Kymera Therapeutics stock rating on new trial data |
Das Unternehmen BIO-WORKS TECHNOLOGIES AB kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell +6,48 % bei einem Aktienkurs von 0,263 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BIO-WORKS TECHNOLOGIES AB finden Sie auf Wallstreet Online.